- Market Capitalization, $K 10,527,738
- Shares Outstanding, K 1,092,089
- Annual Sales, $ 18,854 M
- Annual Income, $ -2,150,000 K
- 60-Month Beta 1.83
- Price/Sales 0.57
- Price/Cash Flow 2.12
- Price/Book 0.72
|Period||Period Low||Period High||Performance|
| || |
-0.14 (-1.43%)since 11/13/19
| || |
+1.70 (+21.41%)since 09/13/19
| || |
-9.38 (-49.32%)since 12/13/18
Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.
InvestorsObserver issues critical PriceWatch Alerts for AAPL, GE, M, NIO, and TEVA.
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") to purchase for cash...
The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.
Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) ("Teva") announced today that it successfully upsized and priced approximately $2.1 billion (equivalent) of its senior notes (the "Notes")....
A lot of cancer research is dealing with shrinking brain tumors and opening the door for targeted cancer therapies to work without damaging the surrounding tissue. The success rate for cancer therapies...
|Teva Pharmaceutical Industries Ltd|
|Pharmaceutical Vaneck ETF|
|Bldrs Europe Select ADR Index Fund Invesco|
|Bldrs Developed Markets 100 ADR Index Fund Inves|
|GS Activebeta International ETF|
|Schwab Fundamental Intl Large Company|